1.1 Idiopathic |
1.2 Heritable (BMPR2, ALK1, endoglin, unknown) |
1.3 Drugs and toxins induced |
1.4 Associated with (APAH): connective tissue diseases, HIV infection, Portal Hypertension, Congenital heart disease, Schistosomiasis, Chronic haemolytic anemia |
1.5 Persistent pulmonary hypertension of the newborn |
Group 1’: Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis |
Group 2: Pulmonary hypertension due to left heart disease |
2.1 Systolic dysfunction |
2.2 Diastolic dysfunction |
2.3 Valvular disease |
Group 3: Pulmonary hypertension due to lung diseases and/or hypoxaemia |
3.1 Chronic obstructive pulmonary disease |
3.2 Interstitial lung disease |
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern |
3.4 Sleep disordered breathing |
3.5 Alveolar hypoventilation disorders |
3.6 Chronic exposure to high altitude |
3.7 Developmental abnormalities |
Group 4: Chronic thromboembolic pulmonary hypertension |
Group 5: Pulmonary hypertension with unclear and/or multifactorial mechanisms |
5.1 Hematological disorders: myeloproliferative disorders, splenectomy |
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell hystiocitosis, lymphangioleiomyomatosis, neurofibromatosis, vasculitis |
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders |
5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic renal failure on dialysis |